LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Lista de Ações・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

24.04 2.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.18

Máximo

24.25

Indicadores-chave
By Trading Economics
Rendimento	10M 17M
Vendas	30M 130M
EPS	0.13
Margem de lucro	13.432
Funcionários	354
EBITDA	11M 22M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+47.94% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-285M 2.9B
Abertura anterior	21.57
Fecho anterior	24.04

Sentimento de Notícias

By Acuity

66%

34%

305 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

12.42 / 14.93 Suporte e Resistência

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 23:41 UTC

Ganhos

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 de mai. de 2026, 21:40 UTC

Ganhos

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 de mai. de 2026, 23:12 UTC

Ganhos

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:07 UTC

Ganhos

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 de mai. de 2026, 23:05 UTC

Ganhos

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 de mai. de 2026, 23:04 UTC

Ganhos

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 de mai. de 2026, 22:25 UTC

Conversa de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 de mai. de 2026, 22:05 UTC

Conversa de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 de mai. de 2026, 21:58 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:47 UTC

Conversa de Mercado

Ganhos

Costco Posts 13% Sales Growth in April -- Market Talk

6 de mai. de 2026, 21:46 UTC

Ganhos

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 de mai. de 2026, 21:40 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:35 UTC

Conversa de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 de mai. de 2026, 21:32 UTC

Ações em Alta

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 de mai. de 2026, 21:29 UTC

Ganhos

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

47.94% parte superior

Previsão para 12 meses

Média 34.75 USD 47.94%

Máximo 36 USD

Mínimo 33 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimento

By Acuity

305 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.